Bacterial Infections

A commercial perspective

Disclaimer:  The information below is for educational purposes only and is not intended to provide medical advice.

April 19, 2026 – This is a living document that is updated regularly as new information becomes available. If you need something sooner, please email rick.beasley@obis.com and I can update the webpage.

By Rick Beasley, BSChE, MBA, MSc Molecular Medicine

 

Commercialization –

Global bacterial mortality by genus, 2019

Deaths associated with 33 bacterial pathogens rolled up to genus level — all ages, all infectious syndromes, 204 countries.
Includes both antimicrobial-susceptible and resistant strains.

Total deaths
7.7M
95% UI: 5.7M–10.2M
Share of global deaths
13.6%
All-cause, 2019
Top 5 genera
55%
of all bacterial deaths
Genera ranked
25
from 33 pathogens

Click any row to expand species breakdown and footnote.

# Genus Est. deaths (2019)
Note on Mycobacterium tuberculosis: TB (~1.21 million deaths in 2019) is excluded from this ranking. The source study omitted it because WHO/GBD already maintain a dedicated TB surveillance stream. If included, Mycobacterium would rank approximately 3rd–4th globally.
Note on Helicobacter pylori: Helicobacter is responsible for an estimated ~500,000–700,000 deaths per year, primarily through gastric (stomach) cancer. Gastric cancer causes roughly 660,000–770,000 deaths annually, of which about 70–80% are attributable to H. pylori. This pathogen is not included in the 33-pathogen Lancet analysis above because its mortality burden is typically classified under cancer rather than acute infectious syndromes.

Sources: Global gastric cancer mortality estimates (e.g., GLOBOCAN) and studies of population-attributable fraction for H. pylori infection.
Note on Treponema pallidum (syphilis): Syphilis is estimated to cause 70,541 deaths globally per year, largely through congenital infection. This pathogen is not included in the 33-pathogen Lancet analysis above because it is typically reported through separate disease-specific burden estimates.

Source: Yu, W., You, X., & Luo, W. (2024). Global, regional, and national burden of syphilis, 1990–2021 and predictions by Bayesian age–period–cohort analysis: a systematic analysis for the global burden of disease study 2021. Frontiers in Medicine, 11, 1448841. https://doi.org/10.3389/fmed.2024.1448841
Note on Bacillus: No formal global mortality estimate exists for this genus. Human disease is rare and primarily due to Bacillus anthracis (anthrax), with roughly ~2,000 cases reported annually worldwide and highly variable case-fatality rates. Overall mortality is therefore low (likely <1,000 deaths per year) and negligible at the global scale compared to major bacterial pathogens.

Sources: Anthrax epidemiology summaries and systematic reviews of global burden (e.g., CDC; global anthrax burden reviews).
Source: GBD 2019 Antimicrobial Resistance Collaborators. "Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019." The Lancet 2022; 400: 2221–48. DOI: 10.1016/S0140-6736(22)02185-7. Published open access under CC BY 4.0.

Methodology: Genus totals computed by aggregating species-level data from Table 1 (pp. 2225–2229) of the source paper. Where the source reported "spp." aggregates (e.g., Enterobacter spp., Campylobacter spp.), those totals were used directly. Deaths represent the central estimate; 95% uncertainty intervals are reported in the expanded footnote for each genus.
Antibiotic Class Target / Mechanism Drug Examples
Aminoglycosides Bind the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis; classically concentration-dependent and bactericidal. Amikacin, gentamicin, tobramycin
β-Lactams Bind penicillin-binding proteins (PBPs) and inhibit transpeptidation/cross-linking of peptidoglycan, weakening the bacterial cell wall and leading to cell lysis. Amoxicillin, ampicillin, cefazolin, ceftriaxone, meropenem, piperacillin-tazobactam
Carbapenems β-Lactam subclass with broad-spectrum cell-wall activity; bind PBPs and inhibit peptidoglycan cross-linking. Ertapenem, imipenem-cilastatin, meropenem
Cephalosporins β-Lactam subclass that inhibits bacterial cell-wall synthesis by binding PBPs; activity varies by generation. Cefazolin, cefepime, cephalexin, ceftriaxone
Fluoroquinolones Inhibit DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and repair. Ciprofloxacin, levofloxacin, moxifloxacin
Glycopeptides Bind the D-Ala-D-Ala terminus of cell-wall precursors, blocking peptidoglycan polymerization and cross-linking. Teicoplanin, vancomycin
Lincosamides Bind the 50S ribosomal subunit and inhibit peptide-chain elongation/translocation, suppressing protein synthesis. Clindamycin
Macrolides Bind the 50S ribosomal subunit and inhibit translocation, reducing bacterial protein synthesis. Azithromycin, clarithromycin, erythromycin
Nitroimidazoles Under anaerobic conditions, reduced intermediates damage DNA and cause strand breakage. Metronidazole
Oxazolidinones Bind the 50S ribosomal subunit and prevent formation of the initiation complex for protein synthesis. Linezolid, tedizolid
Penicillins β-Lactam subclass that binds PBPs and inhibits peptidoglycan cross-linking in the bacterial cell wall. Amoxicillin, amoxicillin-clavulanate, ampicillin, penicillin G, penicillin V, piperacillin-tazobactam
Sulfonamides / Folate Antagonists Block sequential steps in folate synthesis: sulfonamides inhibit dihydropteroate synthase and trimethoprim inhibits dihydrofolate reductase. Sulfadiazine, sulfamethoxazole-trimethoprim
Tetracyclines Bind the 30S ribosomal subunit and prevent aminoacyl-tRNA binding at the A site, inhibiting protein synthesis. Doxycycline, minocycline, tetracycline

Bacteria Table

Genus Gram Shape Oxygen Biofilm / Capsule / Spores Key toxins Other virulence factors
Bacillus
e.g. B. anthracis 		Gram positive Rod Facultative anaerobe Biofilm, capsule, spore Anthrax toxin Plasmids (pXO1, pXO2)
Clostridioides
e.g. C. difficile 		Gram positive Rod Obligate anaerobe Biofilm, spore Toxin A, Toxin B Antibiotic-associated overgrowth
Escherichia
e.g. E. coli 		Gram negative Rod Facultative anaerobe Biofilm Shiga toxin; LT/ST Fimbriae, LPS, adhesins
Helicobacter
e.g. H. pylori 		Gram negative Spiral Microaerophilic Biofilm VacA, CagA Urease, flagella
Mycobacterium
e.g. M. tuberculosis 		Acid-fast Variable Obligate aerobe Biofilm None Intracellular survival, lipid-rich wall
Mycoplasma
e.g. M. pneumoniae 		No cell wall Pleomorphic Facultative anaerobe Biofilm None Adhesins (P1), antigenic variation
Salmonella
e.g. S. enterica 		Gram negative Rod Facultative anaerobe Biofilm LPS; enterotoxins Type III secretion, macrophage survival, secretes bacterial membrane vesicles (BMVs) which facilitate uptake by host (ruffling)
Staphylococcus
e.g. S. aureus 		Gram positive Variable Facultative anaerobe Biofilm, capsule TSST-1, PVL, alpha-toxin Protein A, adhesins
Streptococcus
e.g. S. pneumoniae 		Gram positive Coccus Facultative anaerobe Biofilm, capsule Hemolysins, exotoxins M protein, immune evasion
Treponema
e.g. T. pallidum 		Gram negative Spirochete Microaerophile — None Endoflagella, immune evasion

Bacterial Exotoxins

Four Major Classes of Bacterial Exotoxins
Grouped by how they interact with host cells

  • Class 1: Bind host receptors → alter cell signaling
  • Class 2: Disrupt membranes → pore formation or lipid damage
  • Class 3: A–B toxins → bind, enter, enzymatically damage
  • Class 4: Injected toxins → delivered directly into host cells

Key concept:
Classes 1–3 act from outside the cell; Class 4 is injected directly inside.